- No file added yet -

Supplemental Table 5 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors

figure

posted on 2023-03-31, 19:02 authored by Vasilis Bikos, Maria Karypidou, Evangelia Stalika, Panagiotis Baliakas, Aliki Xochelli, Lesley-Ann Sutton, George Papadopoulos, Andreas Agathangelidis, Evdoxia Papadopoulou, Zadie Davis, Patricia Algara, George Kanellis, Alexandra Traverse-Glehen, Manuela Mollejo, Achilles Anagnostopoulos, Maurilio Ponzoni, David Gonzalez, Sarka Pospisilova, Estella Matutes, Miguel Angel Piris, Theodora Papadaki, Paolo Ghia, Richard Rosenquist, David Oscier, Nikos Darzentas, Dimitrios Tzovaras, Chrysoula Belessi, Anastasia Hadzidimitriou, Kostas Stamatopoulos

Recurrent amino acid replacements. Counts and distribution per IGHV gene and V-subregion. Respective physicochemical characteristics of the substitutions

Funding

EU Seventh Framework

Hellenic Association for Molecular Cancer Research

EU Seventh Framework Programme

History

ARTICLE ABSTRACT

Purpose: Prompted by the extensive biases in the immunoglobulin (IG) gene repertoire of splenic marginal-zone lymphoma (SMZL), supporting antigen selection in SMZL ontogeny, we sought to investigate whether antigen involvement is also relevant post-transformation.Experimental Design: We conducted a large-scale subcloning study of the IG rearrangements of 40 SMZL cases aimed at assessing intraclonal diversification (ID) due to ongoing somatic hypermutation (SHM).Results: ID was identified in 17 of 21 (81%) rearrangements using the immunoglobulin heavy variable (IGHV)1-2*04 gene versus 8 of 19 (40%) rearrangements utilizing other IGHV genes (P = 0.001). ID was also evident in most analyzed IG light chain gene rearrangements, albeit was more limited compared with IG heavy chains. Identical sequence changes were shared by subclones from different patients utilizing the IGHV1-2*04 gene, confirming restricted ongoing SHM profiles. Non-IGHV1-2*04 cases displayed both a lower number of ongoing SHMs and a lack of shared mutations (per group of cases utilizing the same IGHV gene).Conclusions: These findings support ongoing antigen involvement in a sizable portion of SMZL and further argue that IGHV1-2*04 SMZL may represent a distinct molecular subtype of the disease. Clin Cancer Res; 22(8); 2032–40. ©2015 AACR.

Usage metrics

Keywords

Biomarkers Hematological Cancers Leukemias

Licence

CC BY

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM